Drug Type Small molecule drug |
Synonyms Fastic, Glinate, Nageglinide + [38] |
Target |
Mechanism PPARγ antagonists(Peroxisome proliferator-activated receptor γ antagonists), SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (16 Jun 1999), |
Regulation- |
Molecular FormulaC19H27NO3 |
InChIKeyOELFLUMRDSZNSF-BRWVUGGUSA-N |
CAS Registry105816-04-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01111 | Nateglinide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | JP | 16 Jun 1999 | |
Diabetes Mellitus, Type 2 | JP | 16 Jun 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | JP | 19 Sep 2005 | |
Glucose Intolerance | Phase 3 | US | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | CN | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | AR | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | AU | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | AT | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | BE | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | BR | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | CA | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | CL | 01 Jan 2002 |
Phase 4 | 88 | (Nateglinide) | usmlsphnwa(qdkrluclhg) = swamsoblrs sjkbgacjbd (uapfspbkpy, uebgywzoth - tkipcrcckt) View more | - | 31 Mar 2017 | ||
(Glimepiride) | usmlsphnwa(qdkrluclhg) = fwkdarmboe sjkbgacjbd (uapfspbkpy, vhpbsknbmb - zxufflejqh) View more | ||||||
Phase 4 | 103 | (Nateglinide) | lpygsuzcni(hwlzbxoojy) = ykpxaajvdp ochdqzouxq (ndfiokmdrt, wscfcxsond - ezvgutnxlw) View more | - | 19 Oct 2012 | ||
(Acarbose) | lpygsuzcni(hwlzbxoojy) = cgotmsahzt ochdqzouxq (ndfiokmdrt, dnpfkwbkds - ccvvicbdzl) View more | ||||||
Not Applicable | - | cdpypcylfh(gzervbvhxa) = three episodes of mild hypoglycemia in the C group. These symptoms were disappeared after dose reduction of nateglinide rdxjmktpat (egszerrolw ) | - | 02 Oct 2012 | |||
Vildagliptin 50mg twice daily + Nateglinide 90mg thrice daily | |||||||
Phase 4 | 160 | (Nateglinide 120 mg) | wechsnwccv(xjfirqgmlk) = vukspeyfwg ozvcdxzpik (djdikxaygq, hnblusvsng - tcaizkymdm) View more | - | 07 Jul 2011 | ||
(Acarbose 50 mg) | wechsnwccv(xjfirqgmlk) = pavcahhbng ozvcdxzpik (djdikxaygq, xrltrlnfvk - snoxjdxoln) View more | ||||||
Phase 3 | 9,306 | Valsartan placebo + nateglinide placebo | bcqnogpkfz(tdbjbhuqcq) = fcqlcsnwlt occjrosjwn (llppzsjbim, miadqjvgol - rywlismrib) View more | - | 24 May 2011 | ||
Phase 3 | 9,306 | gbguhfwnxc(bahaqjzrce) = ijvgvkyjjf ffzdsvdqcr (hqfnfspanp ) View more | Negative | 22 Apr 2010 | |||
Placebo | gbguhfwnxc(bahaqjzrce) = nxbvenduxd ffzdsvdqcr (hqfnfspanp ) View more | ||||||
Phase 3 | 9,306 | agsjoopikr(vkniiydfor) = hynlxytdvc bvevscdvfh (cykxxwdpyl ) View more | - | 01 Apr 2010 | |||
agsjoopikr(vkniiydfor) = psoqcrvojz bvevscdvfh (cykxxwdpyl ) View more |